SGLT-2 Inhibitor: Difference between revisions
(Add See Also section) |
|||
| Line 19: | Line 19: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | *Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | ||
==See Also== | |||
*[[Diabetes medications]] | |||
*[[Diabetic ketoacidosis]] | |||
*[[Hyperglycemia]] | |||
==References== | ==References== | ||
Latest revision as of 09:14, 22 March 2026
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule